Malignancy biomarkers are measurable biological indicators, such as molecules, genes, proteins or other quantifiable features, that signal the presence, type, progression or behaviour of cancer. They are used to support diagnosis, distinguish malignant from benign conditions, assess prognosis, guide treatment select…
Malignancy biomarkers are measurable biological indicators, such as molecules, genes, proteins or other quantifiable features, that signal the presence, type, progression or behaviour of cancer. They are used to support diagnosis, distinguish malignant from benign conditions, assess prognosis, guide treatment selection and monitor response and recurrence. Identifying reliable biomarkers is a major focus of cancer research, drawing on techniques from molecular biology, biochemistry and analytical measurement to find indicators that are both accurate and clinically useful. Reflecting the hematology and oncology focus of this journal and its companion titles, related research has explored measurable signals that may help detect or characterise cancer. Studies include the use of prostatic-fluid zinc-to-bromine concentration ratios as a non-invasive screening approach for prostate cancer, and the use of trace-element contents in nodular tissue, determined by neutron activation and mass spectrometry, to distinguish malignant from benign thyroid alterations. This page gathers peer-reviewed, open-access research relevant to malignancy biomarkers and their role in cancer detection, classification and management.
2 peer-reviewed articles, ranked by relevance. Each links to its DOI.
The 2 articles above have been cited 10 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
A sample of recent works citing this journal's research on Malignancy Biomarkers, linking to each citing work.